Stock Groups

AbbVie Earnings Beat, Revenue Misses In Q4 -Breaking

by Mike Robinson

[ad_1]

© Reuters AbbVie Earnings Beat, Revenue Misses In Q4

AbbVie (NYSE 🙂 announced Wednesday that the fourth quarter beat analyst forecasts, and that revenue fell below expectations.

AbbVie reported earnings per share at $3.31 on revenue $14.89B. Investing.com polled analysts to predict EPS of 3.29 on revenue $14.96B.

AbbVie shares have risen 1% since the start of the year. However, they are still down 0.95% from their 52-week high of $138.30 on January 27, but that is still a 1% increase. They are outperforming the S&P 500 which is down 4.61% from the start of the year.

Following the publication, AbbVie stock shares rose 0.72% in premarket trade.

AbbVie reports on other earnings from the healthcare sector in this month

AbbVie’s report follows an earnings beat by J&J on January 25, who reported EPS of $2.13 on revenue of $24.8B, compared to forecasts EPS of $2.12 on revenue of $25.28B.

UnitedHealth exceeded expectations by beating forecasts on January 19, posting fourth quarter EPS at $4.48 per dollar on revenues of $73.74B. This compares to the $4.3 per cent revenue forecast.

Keep up to date with all the earnings reports coming soon by visiting Investing.com’s earnings calendar

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]